US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has entered into a partnership with Dutch biotech Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders.
C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system disorders. Under the terms of the agreement, Alexion will provide Complement Pharma with up to 14 million euros ($16.5 million) in milestone-dependent payments through Phase Ib development.
The agreement also provides Alexion with the option to acquire Complement Pharma during the term of the agreement for an unspecified sum.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze